Latest news

Debiopharm S.A. and GPC Biotech AG Announce Partnering of Small Molecule MHC Class II Antagonists Program for Autoimune Diseases

Debiopharm S.A. and Tulane Cancer Center nominate Dr T. Curiel and Dr W. Zou, the 2004 Mauvernay Research Excellences Scholars

New Data presented on Debiopharm´s Debio-025 at the 11th International Symposium on Hepatits C virus and related viruses

Debiopharm and Watson Pharmaceuticals enter into an Exclusive Licensing Agreement for two approved urology products – Trelstar® DEPOT and Trelstar®…

H3 Pharma Inc. and DSM Biologics sign development agreement for SC-1 monoclonal antibody for the treatment of gastric cancer

Mexico becomes first country to approve H3 Pharma´s Sanvar® for esophageal variecal bleeding and four other indications

Debiopharm´s Eloxatin® (Oxaliplatin) awarded Prix Galien in France for innovative cancer therapy

Debiopharm exercises its Option and signs a License Agreement with the Shanghai Institute of Materia Medica for the Development and…

Debiopharm´s Pamorelin Long Acting, Formulated Using Debio® PLGA Technology, receives Final Marketing Autorisation in Germany